Pharmacological rescue of GCase activity using recombinant GCase or chemical chaperones will allow further exploration of the mechanisms by which GBA-N370S mutation leads to the developmental defects observed and may provide promising therapeutic strategies to treat PD. This evidence concerns the gene GBA1 and Parkinson disease.